3/14
Cancer Research
Text message tool addresses ‘time toxicity’ for cancer patients
Text message tool addresses ‘time toxicity’ for cancer patients
In pilot study from Penn Medicine, patients saved over an hour of time at every treatment visit using digital technology.
No evidence that CAR T cell therapy causes secondary cancers
No evidence that CAR T cell therapy causes secondary cancers
In a new study, researchers at Penn Medicine looked for—and did not find—examples where the process of generating CAR T cells caused malignancy.
The compassionate team behind CAR T cancer breakthroughs
The compassionate team behind CAR T cancer breakthroughs
The clinical trial support staff at Penn Medicine and the Abramson Cancer Center have helped execute the team science that brings research discoveries from the lab bench to the bedside.
New ways to modulate cell activity remotely
New ways to modulate cell activity remotely
Penn researchers use temperature to guide cellular behavior, promising better diagnostics and targeted therapies.
Developing a tiny anticancer weapon
Developing a tiny anticancer weapon
Penn Medicine researchers have developed tumor-homing nanosized particles that trigger cancer cell self-destruction in preclinical tests.
Discovery links cellular structures to kidney cancer treatment outcomes
Discovery links cellular structures to kidney cancer treatment outcomes
New research from Penn Medicine finds patterns in cells of tumors may guide personalized therapies for clear cell renal cell carcinoma.
New tool puts reproductive risk for BRCA carriers into perspective
New tool puts reproductive risk for BRCA carriers into perspective
A team at Penn Medicine has created a resource to help inform reproductive counseling for cancer gene mutation carriers.
Generic platinum chemotherapy shortages did not increase deaths
Generic platinum chemotherapy shortages did not increase deaths
A national data analysis finds that short-term mortality was not impacted by the shortage for patients with advanced cancers.
Brain tumor organoids accurately model patient response to CAR T cell therapy
Brain tumor organoids accurately model patient response to CAR T cell therapy
Lab-grown tumors respond to cell therapy the same as tumors in the patients’ brains, according to researchers at Penn Medicine.
Keto diet metabolite may power up CAR T cells to kill cancer
Keto diet metabolite may power up CAR T cells to kill cancer
Laboratory studies reveal a potentially low-tech intervention to improve personalized cell therapy.
In the News
Science News
A child who got CAR-T cancer therapy is still disease-free 18 years later
Carl June of the Perelman School of Medicine says that neuroblastoma is the first solid tumor for which there could be curative effects with CAR T cells.
FULL STORY →
The Hill
The U.S. is losing its next generation of health scientists
In a co-written opinion essay, James Alwine of the Perelman School of Medicine says that slashing of research funding for NIH and the National Science Foundation will eliminate the next generation of health scientists.
FULL STORY →
Interesting Engineering
Scientists create tiny anticancer weapons that make tumors destroy themselves
Xiaowei (George) Xu of the Perelman School of Medicine and colleagues have unveiled an innovative approach to cancer treatment that leverages tiny capsules known as small extracellular vesicles to target a specific receptor on tumor cells.
FULL STORY →
HealthDay
Keto diet supplement could boost a cancer treatment's effectiveness
A study by Perelman School of Medicine student Puneeth Guruprasad and postdoc Shan Liu suggests that a component of the keto diet could boost CAR T cell therapy to help treat cancer.
FULL STORY →
Forbes
Carl June: 2024 will be seen as a breakthrough year for brain cancer
Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.
FULL STORY →
Philadelphia Inquirer
Penn plans to build a proton center for cancer treatment at Presbyterian Medical Center
Penn Medicine will build its fourth proton beam center for cancer treatment at Penn Presbyterian Medical Center in University City.
FULL STORY →